Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8692

Salicylazosulfapyridine: Target Organs and Levels of Evidence for TR-457

Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CASRN 599-79-1) in F344 Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Salicylazosulfapyridine
599-79-1		 Gavage
R: 0, 84, 169, OR 337 M: 0, 675, 1350, OR 2700 MG/KG		 T.S.I. Mason Laboratories, Inc.

Levels of Evidence: None



Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Salicylazosulfapyridine
599-79-1		 06/20/1995 Gavage
R: 84, 168, OR 337.5 MG/KG; 70/GROUP M: 675, 1350, OR 2700 MG/KG; 60/GROUP		 Southern Research Institute

Levels of Evidence

Male Rats: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Urinary Bladder: (CORE STUDY) TRANSITIONAL CELL PAPILLOMA 0/50 0/49 2/50 6/50
Non-Neoplastic Lesions
  • URINARY BLADDER: (CORE STUDY) CONCRETION; DILATATION; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA
  • KIDNEY: (CORE STUDY) CONCRETION; HYDRONEPHROSIS; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA; MINERALIZATION; RENAL TUBULE DILATATION
  • SPLEEN: (CORE AND STOP STUDY) HEMOSIDEROSIS; HEMATOPOIETIC CELL PROLIFERATION
Other Considerations
  • VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 13/50 18/50 12/50 3/50
Female Rats: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Transitional Cell: PAPILLOMA 0/50 0/50 0/50 2/50
  • Urinary Bladder: TRANSITIONAL CELL PAPILLOMA 0/49 0/50 2/50 0/50
Non-Neoplastic Lesions
  • URINARY BLADDER: HYPERPLASIA
  • KIDNEY: CONCRETION; TRANSITIONAL CELL HYPERPLASIA; HYDRONEPHROSIS; NEPHROPATHY
Other Considerations
  • VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 14/50 9/50 8/50 3/50
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 13/50 32/50 28/50 42/50 OR CARCINOMA 13/50 15/50 23/50 8/50 COMBINED 24/50 38/50 38/50 44/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
Other Considerations
  • FORESTOMACH: HYPERPLASIA 18/50 11/50 11/49 10/50
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 12/50 28/50 25/50 28/49 OR CARCINOMA 2/50 10/50 10/50 9/49 COMBINED 14/50 32/50 28/50 29/49
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
Other Considerations
  • FORESTOMACH: SQUAMOUS CELL PAPILLOMA 5/50 1/50 1/50 0/50; HYPERPLASIA 12/50 6/49 4/50 4/49


Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Salicylazosulfapyridine
599-79-1		 06/20/1995 Gavage Southern Research Institute

Levels of Evidence

Male Rats: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Urinary Bladder: (CORE STUDY) TRANSITIONAL CELL PAPILLOMA 0/50 0/49 2/50 6/50
Non-Neoplastic Lesions
  • URINARY BLADDER: (CORE STUDY) CONCRETION; DILATATION; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA
  • KIDNEY: (CORE STUDY) CONCRETION; HYDRONEPHROSIS; (CORE AND STOP STUDY) TRANSITIONAL CELL HYPERPLASIA; MINERALIZATION; RENAL TUBULE DILATATION
  • SPLEEN: (CORE AND STOP STUDY) HEMOSIDEROSIS; HEMATOPOIETIC CELL PROLIFERATION
Other Considerations
  • VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 13/50 18/50 12/50 3/50
Female Rats: Some Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Kidney Transitional Cell: PAPILLOMA 0/50 0/50 0/50 2/50
  • Urinary Bladder: TRANSITIONAL CELL PAPILLOMA 0/49 0/50 2/50 0/50
Non-Neoplastic Lesions
  • URINARY BLADDER: HYPERPLASIA
  • KIDNEY: CONCRETION; TRANSITIONAL CELL HYPERPLASIA; HYDRONEPHROSIS; NEPHROPATHY
Other Considerations
  • VARIOUS ORGANS: MONONUCLEAR CELL LEUKEMIA 14/50 9/50 8/50 3/50
Male Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 13/50 32/50 28/50 42/50 OR CARCINOMA 13/50 15/50 23/50 8/50 COMBINED 24/50 38/50 38/50 44/50
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
Other Considerations
  • FORESTOMACH: HYPERPLASIA 18/50 11/50 11/49 10/50
Female Mice: Clear Evidence
Type Organ/Tissue (Lesion)
Neoplastic Lesions
  • Liver: ADENOMA 12/50 28/50 25/50 28/49 OR CARCINOMA 2/50 10/50 10/50 9/49 COMBINED 14/50 32/50 28/50 29/49
Non-Neoplastic Lesions
  • LIVER: EOSINOPHILIC FOCI
  • SPLEEN: HEMATOPOIETIC CELL PROLIFERATION; HEMOSIDEROSIS
Other Considerations
  • FORESTOMACH: SQUAMOUS CELL PAPILLOMA 5/50 1/50 1/50 0/50; HYPERPLASIA 12/50 6/49 4/50 4/49